LEUKOREDUCTION OF PLATELETS BY PULSED ELECTRIC FIELDS

通过脉冲电场减少血小板白细胞

• 批准号: 6551935
• 负责人: ABIE CRAIU
• 金额: $ 10万
• 依托单位: SCIENCE RESEARCH LABORATORY, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6551935
• 关键词: biomedical equipment development; clinical research; electrical potential; electromagnetic radiation; electroporation; human tissue; leukocyte activation /transformation; leukocyte depletion therapy; magnetic field; platelets; tissue /cell preparation

DESCRIPTION (provided by applicant): This proposal addresses the utility of pulsed electric field (PEF) technology for leukoreduction of platelet products. Leukocytes in platelet products can cause several complications in recipients of platelet transfusions, including alloiommunization, febrile reactions, viral infection and fraft-versus-host disease. There is a global drive towards implementing universal leukoreduction of platelet products on the day of collection. Filtration is currently the only method leukoreducing platelet products, but this technique results in only between 3 and 4-logs of leukocyte purging, is expensive and time-consuming, and may be difficult to implement on the day of platelet collection. We have demonstrated that PEFs of intermediate strength selectively purge leukocytes (>3-logs) and preserve platelet counts. We expect that more thorough leukoreduction (>5-logs) can easily be achieved using higher electric field strengths, without affecting platelet count and viability. We recently developed a flowing PEF apparatus for rapid treatment of clinical quantities of blood products. In phase I, this apparatus will be used to optimize operating parameters for leukoreduction. Levels of leukodepletion and platelet yield and viability will be critically assessed. Phase II will develop a PEF prototype apparatus for convenient and thorough leukodepletion on the day of collection, compatible with current platelet collection methodologies.

描述（由申请人提供）：该提案介绍了脉冲电场（PEF）技术用于血小板产品的效用。 血小板产物中的白细胞可能会导致血小板输血的受体几种并发症，包括同种共和性，发热反应，病毒感染和融资 - 抗宿主病。 在收集当天，全球努力实施血小板产品的普遍白细胞化。 过滤是白细胞产品的唯一方法，但是该技术仅导致3至4 logs的白细胞清除，昂贵且耗时，并且在血小板收集当天可能难以实施。 我们已经证明了中间强度的PEF选择性地清除白细胞（> 3 logs）并保留血小板计数。 我们期望使用较高的电场强度可以轻松实现更彻底的白细胞量（> 5杆），而不会影响血小板计数和活力。 我们最近开发了一种流动的PEF设备，用于快速治疗临床数量的血液产品。 在第一阶段，该设备将用于优化白细胞制剂的工作参数。 白细胞增多和血小板产量和生存能力的水平将进行严格评估。 第二阶段将开发PEF原型设备，以便在收集当天方便而彻底的白细胞序列，与当前的血小板收集方法兼容。